Q3 Earnings Forecast for AGIO Issued By HC Wainwright

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) – HC Wainwright issued their Q3 2026 earnings per share (EPS) estimates for Agios Pharmaceuticals in a research note issued to investors on Thursday, October 29th. HC Wainwright analyst D. Tsao expects that the biopharmaceutical company will earn ($1.26) per share for the quarter. HC Wainwright has a “Buy” rating and a $55.00 price objective on the stock. The consensus estimate for Agios Pharmaceuticals’ current full-year earnings is ($5.85) per share. HC Wainwright also issued estimates for Agios Pharmaceuticals’ Q4 2026 earnings at ($1.42) EPS, FY2026 earnings at ($6.05) EPS, FY2027 earnings at ($4.61) EPS, FY2028 earnings at ($2.92) EPS, FY2029 earnings at ($1.61) EPS and FY2030 earnings at $0.72 EPS.

Other equities analysts also recently issued research reports about the stock. Royal Bank Of Canada raised their price objective on shares of Agios Pharmaceuticals from $28.00 to $32.00 and gave the stock a “sector perform” rating in a report on Tuesday, July 7th. Weiss Ratings reaffirmed a “sell (d)” rating on shares of Agios Pharmaceuticals in a report on Monday, September 21st. JPMorgan Chase & Co. increased their price target on shares of Agios Pharmaceuticals from $31.00 to $34.00 and gave the stock a “neutral” rating in a research report on Friday, August 7th. Citigroup lifted their price target on shares of Agios Pharmaceuticals from $46.00 to $52.00 and gave the stock a “buy” rating in a research note on Friday, July 31st. Finally, Truist Financial cut their price objective on shares of Agios Pharmaceuticals from $39.00 to $37.00 and set a “buy” rating for the company in a research report on Wednesday, October 7th. One equities research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, three have given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $41.50.

Agios Pharmaceuticals Stock Up 4.2%

Agios Pharmaceuticals stock opened at $31.20 on Monday. Agios Pharmaceuticals has a 52-week low of $22.24 and a 52-week high of $46.00. The company has a market cap of $1.86 billion, a P/E ratio of -4.45 and a beta of 0.66. The business has a 50-day simple moving average of $33.53 and a two-hundred day simple moving average of $31.72.

Institutional Trading of Agios Pharmaceuticals

Institutional investors and hedge funds have recently modified their holdings of the company. AlphaCentric Advisors LLC grew its position in shares of Agios Pharmaceuticals by 3.9% during the third quarter. AlphaCentric Advisors LLC now owns 14,731 shares of the biopharmaceutical company’s stock valued at $490,000 after purchasing an additional 558 shares in the last quarter. Nykredit A S bought a new stake in shares of Agios Pharmaceuticals in the second quarter worth about $26,000. Quantinno Capital Management LP lifted its position in shares of Agios Pharmaceuticals by 2.7% in the first quarter. Quantinno Capital Management LP now owns 27,591 shares of the biopharmaceutical company’s stock worth $933,000 after buying an additional 736 shares in the last quarter. Inspire Investing LLC lifted its position in shares of Agios Pharmaceuticals by 4.7% in the third quarter. Inspire Investing LLC now owns 19,130 shares of the biopharmaceutical company’s stock worth $636,000 after buying an additional 861 shares in the last quarter. Finally, VIRGINIA RETIREMENT SYSTEMS ET Al lifted its position in shares of Agios Pharmaceuticals by 4.0% in the third quarter. VIRGINIA RETIREMENT SYSTEMS ET Al now owns 28,861 shares of the biopharmaceutical company’s stock worth $960,000 after buying an additional 1,100 shares in the last quarter.

Insiders Place Their Bets

In other Agios Pharmaceuticals news, insider Sarah Gheuens sold 7,866 shares of the company’s stock in a transaction that occurred on Monday, October 26th. The shares were sold at an average price of $37.69, for a total value of $296,469.54. Following the completion of the transaction, the insider directly owned 54,645 shares in the company, valued at $2,059,570.05. This represents a 12.58% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 9,855 shares of company stock worth $371,112 over the last quarter. 5.40% of the stock is owned by insiders.

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc is a biopharmaceutical company focused on discovering and developing medicines for rare diseases involving cellular metabolism. The company’s research is centered on metabolic pathways that influence red blood cell production and function, with the goal of addressing conditions that have limited treatment options.

Agios’ principal commercial product is Pyrukynd (mitapivat), an oral activator of pyruvate kinase. Pyrukynd is approved in the United States and other markets for the treatment of hemolytic anemia in adults with pyruvate kinase deficiency, a rare inherited blood disorder.